Daiwa Securities Group Inc. Mirati Therapeutics, Inc. Transaction History

Daiwa Securities Group Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$41.99 - $62.38 $2,309 - $3,430	55 Added 23.71%	287 $17,000
Q4 2022 Feb 06, 2023	BUY	$41.27 - $98.62 $1,031 - $2,465	25 Added 12.08%	232 $11,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $1,801 - $4,080	46 Added 28.57%	207 $14,000
Q4 2021 Feb 03, 2022	SELL	$132.01 - $190.29 $2,112 - $3,044	-16 Reduced 9.04%	161 $24,000
Q3 2021 Nov 05, 2021	BUY	$132.13 - $177.45 $10,174 - $13,663	77 Added 77.0%	177 $31,000
Q1 2021 May 03, 2021	BUY	$158.92 - $221.61 $794 - $1,108	5 Added 5.26%	100 $17,000
Q4 2020 Feb 04, 2021	SELL	$162.05 - $240.27 $24,955 - $37,001	-154 Reduced 61.85%	95 $21,000
Q3 2020 Nov 02, 2020	BUY	$113.26 - $167.27 $792 - $1,170	7 Added 2.89%	249 $41,000
Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $1,325 - $2,207	19 Added 8.52%	242 $19,000
Q4 2019 Jan 31, 2020	SELL	$70.76 - $128.86 $1,910 - $3,479	-27 Reduced 10.8%	223 $29,000
Q3 2019 Nov 04, 2019	BUY	$77.91 - $109.6 $2,025 - $2,849	26 Added 11.61%	250 $19,000
Q1 2019 Apr 26, 2019	SELL	$43.65 - $78.95 $1,658 - $3,000	-38 Reduced 14.5%	224 $16,000
Q4 2018 Feb 05, 2019	BUY	$32.0 - $47.43 $8,384 - $12,426	262 New	262 $11,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.